From: Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
 | M2698 monotherapy (N = 62) | M2698/trastuzumab (N = 13) | M2698/tamoxifen (N = 26) |
---|---|---|---|
Age (years) | |||
< 65 | 45 (72.6) | 9 (69.2) | 18 (69.2) |
65–74 | 12 (19.4) | 3 (23.1) | 4 (15.4) |
75–84 | 5 (8.1) | 1 (7.7) | 4 (15.4) |
Male/female | 21/41 (33.9/66.1) | 0/13 (0/100) | 0/26 (0/100) |
ECOG PS: 0/1 | 20/42 (32.3/67.7) | 3/10 (23.1/76.9) | 13/13 (50/50) |
No. of prior lines of anticancer therapy: 1/2/3/4/ ≥ 5 | 57/47/31/21/16 (91.9/75.8/50.0/33.9/25.8) | 13/12/12/11/9 (100/92.3/92.3/84.6/69.2) | 25/22/23/19/19 (96.2/84.6/88.5/73.1/73.1) |
Prior therapies | |||
Chemotherapy | 55 (88.7) | 13 (100) | 22 (84.6) |
Antibody therapy | 6 (9.7) | 3 (23.1) | 3 (11.5) |
Kinase inhibitor | 4 (6.5) | 1 (7.7) | 7 (26.9) |
Hormonal | 10 (16.1) | 5 (38.5) | 19 (73.1) |
Other | 8 (12.9) | 2 (15.4) | 5 (19.2) |
Primary tumor | |||
Colon | 5 (8.1) | 0 | 0 |
Rectum | 1 (1.6) | 0 | 0 |
Breasta | 8 (12.9) | 13 (100) | 24 (92.3) |
Pancreas | 2 (3.2) | 0 | 0 |
Lung | 4 (6.5) | 0 | 0 |
Endometrium | 5 (8.1) | 0 | 0 |
Salivary gland | 6 (9.7) | 0 | 0 |
Other | 31 (50.0) | 0 | 2 (7.7) |
Tumor molecular alterationsb | |||
AKT1 | 3 (4.8) | 0 | 6 (23.1) |
AKT2 | 2 (3.2) | 0 | 0 |
AKT3 | 2 (3.2) | 0 | 1 (3.8) |
PTEN | 13 (21.0) | 0 | 3 (11.5) |
PIK3CA | 32 (51.6) | 8 (61.5) | 15 (57.7) |
EGFR | 3 (4.8) | 0 | 1 (3.8) |
KRAS | 4 (6.5) | 0 | 0 |
ER +  | 3 (4.8) | 9 (69.2) | 21 (80.8) |
PR +  | 3 (4.8) | 9 (69.2) | 20 (76.9) |
HER 1 +/2 +/3 + | 1/2/0 (1.6/3.2/0) | 2/3/7 (15.4/23.1/53.8) | 5/3/1 (19.2/11.5/3.8) |